We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Dexmedetomidine Premedication on Geriatric Patients With Chronic Renal Failure Undergoing Hip Surgery

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01837290
First Posted: April 23, 2013
Last Update Posted: January 27, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Pinar Ergenoglu, Baskent University
  Purpose

Geriatric patients (age ≥ 65 years) undergo surgery for hip fractures that develops due to osteoporosis and falls. Dialysis-dependent chronic kidney disease is associated with an increased risk of cardiovascular comorbidity. Elective or urgent surgical operations may be required for geriatric patients with end stage renal disease. These patients have severe comorbidities, fluid, electrolyte disturbances and drug metabolism abnormalities during the perioperative period. For this reasons a careful anesthesia plan should be planned and performed. Spinal anesthesia can be used for hip fracture surgery at geriatric patients with chronic renal failure. Anterograde femoral intramedullary nailing can be performed in supine position with a fracture table. Intraoperative sedation might be necessary for patients under regional anesthesia on traction table. Dexmedetomidine is an alpha 2 receptor agonist that is being used as an agent for its sedative and adjuvant analgesic effects.

The aim of this study is to evaluate the effects of dexmedetomidine premedication on geriatric patients with end stage renal disease, who will be undergoing a surgical operation for hip fracture under spinal anesthesia with hyperbaric bupivacaine and BIS (Bispectral Index) guided sedation with intraoperative propofol infusion.


Condition Intervention Phase
Chronic Renal Failure Hip Fracture Drug: dexmedetomidine infusion for premedication Drug: Midazolam Drug: saline infusion Drug: Spinal block with hyperbaric bupivacaine 0.5% 12.5 mg Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Official Title: The Effect of Dexmedetomine Premedication on the Bispectral Index Values Using Sedation With Propofol During Spinal Anesthesia on Geriatric Chronic Renal Failure Patients Undergoing Hip Fracture Surgery The Effect of Dexmedetomine Premedication on the Bispectral Index Values Using Sedation With Propofol During Spinal Anesthesia on Geriatric Chronic Renal Failure Patients Undergoing Hip Fracture Surgery

Resource links provided by NLM:


Further study details as provided by Pinar Ergenoglu, Baskent University:

Primary Outcome Measures:
  • Decrease at the propofol doses and postoperative early recovery [ Time Frame: up to first 6 hours for postoperative pain management ]
    In addition patients will be followed postoperatively first 6 hours for postoperative pain management at the ward.


Enrollment: 60
Study Start Date: December 2012
Study Completion Date: January 2014
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Group Dexmedetomidine (Group D)
Midazolam 0.02 mg/kg intravenously + 0.5 μg/kg/10 min dexmedetomidine infusion for premedication + Spinal block (Hyperbaric bupivacaine 0.5% 12.5 mg) (n=30)
Drug: dexmedetomidine infusion for premedication
Group Dexmedetomidine (Group D): Midazolam 0.02 mg/kg + 0.5 μg/kg/10 min dexmedetomidine infusion for premedication; Spinal block (Hyperbaric bupivacaine 0.5% 12.5 mg) (n=30)
Other Names:
  • Precedex 200mcg/2ml
  • 121/87
  • Hospira İnc., Rocky Mount, NC 27801 USA
Drug: Midazolam
intravenous Midazolam 0.02 mg/kg for premedication
Other Names:
  • Demizolam
  • Dem İlaç San. ve Tic AŞ.
Drug: Spinal block with hyperbaric bupivacaine 0.5% 12.5 mg
Hyperbaric bupivacaine injection for spinal block
Other Names:
  • Marcaine Spinal Heavy 0.5%
  • Astra Zeneca
  • 21.01.2000-194/86
Placebo Comparator: Group Control (Group C)
Midazolam 0.02 mg/kg + saline infusion for premedication; Spinal block (Hyperbaric bupivacaine 0.5% 12.5mg) (n=30)
Drug: Midazolam
intravenous Midazolam 0.02 mg/kg for premedication
Other Names:
  • Demizolam
  • Dem İlaç San. ve Tic AŞ.
Drug: saline infusion
Saline infusion to facilitate blinding
Other Name: 0.9% sodium chloride solution
Drug: Spinal block with hyperbaric bupivacaine 0.5% 12.5 mg
Hyperbaric bupivacaine injection for spinal block
Other Names:
  • Marcaine Spinal Heavy 0.5%
  • Astra Zeneca
  • 21.01.2000-194/86

  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   65 Years to 95 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • elderly patients (above 65 years of age)
  • end stage renal failure on dialysis treatment (Glomerular filtration rate <15, Stage 5)
  • hip fracture

Exclusion Criteria:

  • Patients with decompensated respiratory or heart failure,
  • liver failure
  • morbid obesity
  • mental disorders
  • cognitive disorders
  • language problems
  • patients with a contraindication for regional anesthesia (coagulopathy, history of anticoagulant use, spinal cord disease and patients who rejected spinal anesthesia)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01837290


Locations
Turkey
Baskent University School of Medicine Adana Research and Teaching Center
Adana, Turkey, 01250
Baskent University School of Medicine Adana Teaching and Research Center
Adana, Turkey, 01250
Baskent University School of Medicine Adana Teaching and Research Hospital
Adana, Turkey, 01250
Sponsors and Collaborators
Baskent University
Investigators
Study Director: Anis Aribogan, Prof., MD Baskent University School of Medicine
  More Information

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Pinar Ergenoglu, Specialist Doctor, Anesthesiology and Reanimation Department, Baskent University
ClinicalTrials.gov Identifier: NCT01837290     History of Changes
Other Study ID Numbers: KA12/166
First Submitted: April 17, 2013
First Posted: April 23, 2013
Last Update Posted: January 27, 2015
Last Verified: January 2015

Keywords provided by Pinar Ergenoglu, Baskent University:
Renal failure,
hip fracture,
spinal anesthesia,
dexmedetomidine
patient

Additional relevant MeSH terms:
Fractures, Bone
Renal Insufficiency
Hip Fractures
Kidney Failure, Chronic
Renal Insufficiency, Chronic
Wounds and Injuries
Kidney Diseases
Urologic Diseases
Femoral Fractures
Hip Injuries
Leg Injuries
Bupivacaine
Midazolam
Dexmedetomidine
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Hypnotics and Sedatives
Analgesics, Non-Narcotic
Analgesics
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adjuvants, Anesthesia